> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Aptiom
- URL: https://www.fdaweb.com/review-period-set-for-aptiom/
- Published: 2016-04-12T12:00:00.000Z
- Updated: 2026-09-14T20:54:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135336

FDA has cleared an Oculus Innovative Sciences 510(k) for the Microcyn-based Lasercyn Gel, intended for use for managing post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns, according to the company. “In our clinical testing of Lasercyn to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when Lasercyn is added to the post-procedure management protocol,” it says.

FDA clears an [Oculus Innovative Scienc](http://www.fda.gov/cder?ref=fdaweb.com)es 510(k) for the Microcyn-based Lasercyn Gel, intended for use for managing post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels.